Preclinical News and Research

RSS
Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Combination of TXA709 and cefdinir demonstrates synergistic antibacterial activity against MRSA

Study confirms pathogenic role of beta amyloid in dementia as seen in AD and Down syndrome

Study confirms pathogenic role of beta amyloid in dementia as seen in AD and Down syndrome

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera receives seed investment funding to develop gene therapy for glaucoma

Benitec Biopharma initiates new site for ongoing Phase 1/2a TT-034 trial for hepatitis C

Benitec Biopharma initiates new site for ongoing Phase 1/2a TT-034 trial for hepatitis C

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

USF study shows spleen may be a new target for treating stroke-induced chronic inflammation

USF study shows spleen may be a new target for treating stroke-induced chronic inflammation

BfArM approves Greenovation’s moss-aGal phase I clinical trial for Fabry disease

BfArM approves Greenovation’s moss-aGal phase I clinical trial for Fabry disease

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Combining epigenetic drugs with immunotherapies may provide additional clinical benefit to cancer patients

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

Scientists elucidate genetic interaction that may prove key to development, progression of glaucoma

CureVac, IAVI team up to advance development, testing of AIDS vaccines

CureVac, IAVI team up to advance development, testing of AIDS vaccines

Researchers take new line of approach to combat Alzheimer's disease

Researchers take new line of approach to combat Alzheimer's disease

Innovative vaccine therapy shows promise against glioblastoma brain tumors

Innovative vaccine therapy shows promise against glioblastoma brain tumors

New molecule shows efficacy in inhibiting inflammation, preventing premature delivery in murine models

New molecule shows efficacy in inhibiting inflammation, preventing premature delivery in murine models

Researchers use stem cell-derived 'mini-brains' to identify drug candidate for rare neurological disorder

Researchers use stem cell-derived 'mini-brains' to identify drug candidate for rare neurological disorder

UCSF researchers lead $10 million research project on pediatric cancer

UCSF researchers lead $10 million research project on pediatric cancer

Children's Cancer Institute awarded NCI grant to fast-track new drugs into clinical trials for childhood cancer

Children's Cancer Institute awarded NCI grant to fast-track new drugs into clinical trials for childhood cancer

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

Four Next-Generation Preclinical Imaging Systems introduced

Four Next-Generation Preclinical Imaging Systems introduced

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.